Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Receives Average Recommendation of "Buy" from Analysts

Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Get Free Report) have been given a consensus recommendation of "Buy" by the eight ratings firms that are currently covering the company, MarketBeat reports. Six equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $32.83.

Several equities research analysts have recently weighed in on the stock. Cantor Fitzgerald raised shares of Catalyst Pharmaceuticals to a "strong-buy" rating in a research report on Thursday, June 5th. Robert W. Baird boosted their target price on shares of Catalyst Pharmaceuticals from $28.00 to $32.00 and gave the stock an "outperform" rating in a research report on Monday, March 3rd. HC Wainwright reissued a "buy" rating and issued a $35.00 target price on shares of Catalyst Pharmaceuticals in a research report on Friday, February 28th. Finally, Wall Street Zen raised shares of Catalyst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Friday, February 28th.

Catalyst Pharmaceuticals Stock Down 0.5%

Shares of CPRX traded down $0.11 during midday trading on Wednesday, hitting $21.78. The company had a trading volume of 2,414,054 shares, compared to its average volume of 1,110,491. The company's 50 day moving average price is $23.87 and its 200 day moving average price is $22.90. The stock has a market cap of $2.66 billion, a price-to-earnings ratio of 13.87, a PEG ratio of 0.89 and a beta of 0.72. Catalyst Pharmaceuticals has a 52 week low of $14.97 and a 52 week high of $26.58.

Insider Activity at Catalyst Pharmaceuticals

In other Catalyst Pharmaceuticals news, insider Preethi Sundaram sold 1,600 shares of the company's stock in a transaction dated Wednesday, June 11th. The shares were sold at an average price of $26.42, for a total value of $42,272.00. Following the completion of the transaction, the insider now owns 41,081 shares in the company, valued at approximately $1,085,360.02. This represents a 3.75% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Gary Ingenito sold 200,000 shares of the company's stock in a transaction dated Tuesday, May 13th. The stock was sold at an average price of $23.68, for a total transaction of $4,736,000.00. Following the completion of the transaction, the insider now owns 68,873 shares of the company's stock, valued at approximately $1,630,912.64. This trade represents a 74.38% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 247,924 shares of company stock valued at $5,879,369 in the last quarter. Insiders own 10.40% of the company's stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Steward Partners Investment Advisory LLC bought a new position in Catalyst Pharmaceuticals in the 4th quarter worth about $27,000. Park Square Financial Group LLC bought a new position in shares of Catalyst Pharmaceuticals in the fourth quarter valued at approximately $29,000. Sound Income Strategies LLC bought a new position in shares of Catalyst Pharmaceuticals in the first quarter valued at approximately $64,000. Farther Finance Advisors LLC boosted its holdings in shares of Catalyst Pharmaceuticals by 125.1% in the fourth quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company's stock valued at $56,000 after acquiring an additional 1,495 shares in the last quarter. Finally, GAMMA Investing LLC boosted its holdings in shares of Catalyst Pharmaceuticals by 26.2% in the first quarter. GAMMA Investing LLC now owns 2,791 shares of the biopharmaceutical company's stock valued at $68,000 after acquiring an additional 579 shares in the last quarter. Institutional investors own 79.22% of the company's stock.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.